Molecular and cellular biomarkers in dry eye disease and ocular allergy

Current Opinion in Allergy and Clinical Immunology

Volumn 12, Issue 5, 2012, Pages 523-533

  Enríquez De Salamanca, Amalia ^a,b   Bonini, Stefano ^c   Calonge, Margarita ^a,b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

biomarkers; cytokines chemokines; dry eye disease; inflammation; ocular allergy

Indexed keywords

BIOLOGICAL MARKER; CALGRANULIN A; CALGRANULIN B; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; EOSINOPHIL CATIONIC PROTEIN; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; HEAT SHOCK PROTEIN 70; HEMOPEXIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPID; LIPOCALIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MESSENGER RNA; METALLOPROTEINASE; MUCIN; MUCIN 1; PROTEIN; PROTEINASE ACTIVATED RECEPTOR 2; RANTES; SECRETORY PHOSPHOLIPASE A2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

CELL PROLIFERATION; CELL VIABILITY; CONJUNCTIVA; CORRELATIONAL STUDY; DISEASE SEVERITY; DRY EYE; EPITHELIUM CELL; EYE ALLERGY; HUMAN; LACRIMAL FLUID; LIPIDOMICS; MOLECULE; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SYMPTOM;

BIOLOGICAL MARKERS; CONJUNCTIVITIS, ALLERGIC; CYTOKINES; DRY EYE SYNDROMES; EYE DISEASES; HYPERSENSITIVITY; TEARS;

EID: 84865978977     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e328357b488     Document Type: Review

References (43)

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:75-92.
2. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol 2007; 143:409-415.
3. Calonge M. Classification of ocular atopic/allergic disorders and conditions: an unsolved problem. Acta Ophthalmol Scand Suppl. 1999; 228:10-13.
4. Cook EB. Tear cytokines in acute and chronic ocular allergic inflammation. Curr Opin Allergy Clin Immunol 2004; 4:441-445.
5. Enriquez-de-Salamanca A, Calonge M. Cytokines and chemokines in immunebased ocular surface inflammation. ExpertRev Clin Immunol 2008; 4:457-467.
6. Grus FH, Podust VN, Bruns K, et al. SELDI-TOF-MS ProteinChip array profiling of tears from patients with dry eye. Invest Ophthalmol Vis Sci 2005; 46:863-876.
7. Zhou L, Beuerman RW, Chan CM, et al. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics. J Proteome Res 2009; 8:4889-4905.
8. Tong L, Zhou L, Beuerman RW, et al. Association of tear proteins with Meibomian gland disease and dry eye symptoms. Br J Ophthalmol 2011; 95:848-852.
9. Chen D, Wei Y, Li X, et al. sPLA2-IIa is an inflammatory mediator when the ocular surface is compromised. Exp Eye Res 2009; 88:880-888.
10. Wei Y, Epstein SP, Fukuoka S, et al. sPLA2-IIa amplifies ocular surface inflammation in the experimental dry eye (DE) BALB/c mouse model. Invest Ophthalmol Vis Sci 2011; 52:4780-4788.
11. Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol 2009; 147:198-205.
12. Enriquez-de-Salamanca A, Castellanos E, Stern ME, et al. Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis 2010; 16:862-873.
13. Boehm N, Riechardt AI, Wiegand M, et al. Proinflammatory cytokine profiling of tears from dry eye patients by means of antibody microarrays. Invest Ophthalmol Vis Sci 2011; 52:7725-7730.
14. Tong L, Lee SY, Petznick A. Clinical considerations in proinflammatory cytokine profiling of tears from patients with dry eye by means of antibody microarrays. Invest Ophthalmol Vis Sci 2011; 52:9610.
15. Grus F, Boehm N. Author response: clinical considerations in proinflammatory cytokine profiling of tears from patients with dry eye by means of antibody microarrays. Invest Ophthalmol Vis Sci 2011; 52:9610-9611.
16. Van Der Meid KR, Su SP, Ward KW, Zhang JZ. Correlation of tear inflammatory cytokines and matrix metalloproteinases with four dry eye diagnostic tests. Invest Ophthalmol Vis Sci 2012; 53:1512-1518.
17. Choi W, Li Z, Oh HJ, et al. Expression of CCR5 and its ligands CCL3, -4, and -5 in the tear film and ocular surface of patients with dry eye disease. Curr Eye Res 2012; 37:12-17.
18. Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci 2007; 48:2561-2569.
19. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2009; 2:243-253.
20. Acera A, Rocha G, Vecino E, et al. Inflammatory markers in the tears of patients with ocular surface disease. Ophthalmic Res 2008; 40:315-321.
21. Chotikavanich S, de Paiva CS, Li de Q, et al. Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci 2009; 50:3203-3209.
22. Markoulli M, Papas E, Cole N, Holden BA. The diurnal variation of matrix metalloproteinase-9 and its associated factors in human tears. Invest Ophthalmol Vis Sci 2012; 53:1479-1484.
23. Enríquez-de-Salamanca A, Tesón M, GarcíaN, et al. Cytokine and Chemokine Tear Levels in Healthy Subjects; Intra- and Inter-Day Variation Study. ARVO Meeting abstract 2010; 51:4147
24. Tong L, Petznick A. Correlation between tear matrix metalloproteinases and the Schirmer's test. Invest Ophthalmol Vis Sci 2012; 53:1592.
25. Danjo Y, Watanabe H, Tisdale AS, et al. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci 1998; 39:2602-2609.
26. Argueso P, Balaram M, Spurr-Michaud S, et al. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci 2002; 43:1004-1011.
27. Gipson IK, Hori Y, Argueso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf 2004; 2:131-148.
28. Corrales RM, Narayanan S, Fernandez I, et al. Ocular mucin gene expression levels as biomarkers for the diagnosis of dry eye syndrome. Invest Ophthalmol Vis Sci 2011; 52:8363-8369.
29. Gipson IK, Spurr-Michaud SJ, Senchyna M, et al. Comparison of mucin levels at the ocular surface of postmenopausal women with and without a history of dry eye. Cornea 2011; 30:1346-1352.
30. Caffery B, Heynen ML, Joyce E, et al. MUC1 expression in Sjögren's syndrome, KCS, and control subjects. Mol Vis 2010; 16:1720-1727.
31. Imbert Y, Darling DS, Jumblatt MM, et al. MUC1 splice variants in human ocular surface tissues: possible differences between dry eye patients and normal controls. Exp Eye Res 2006; 83:493-501.
32. Imbert-Fernandez Y, Radde BN, Teng Y, et al. MUC1/A and MUC1/B splice variants differentially regulate inflammatory cytokine expression. Exp Eye Res 2011; 93:649-657.
33. Joffre C, Souchier M, Gregoire S, et al. Differences in meibomian fatty acid composition in patients with meibomian gland dysfunction and aqueousdeficient dry eye. Br J Ophthalmol 2008; 92:116-119.
34. Lam SM, Tong L, Yong SS, et al. Meibum lipid composition in Asians with dry eye disease. PLoS One 2011; 6:e24339.
35. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998; 17:584-589.
36. Lambiase A, Micera A, Sacchetti M, et al. Alterations of tear neuromediators in dry eye disease. Arch Ophthalmol 2011; 129:981-986.
37. Reinoso R, Calonge M, Castellanos E, et al. Differential cell proliferation, apoptosis, and immune response in healthy and evaporative-type dry eye conjunctival epithelia. Invest Ophthalmol Vis Sci 2011; 52:4819-4828.
38. Yeoh S, Church M, Lackie P, et al. Increased conjunctival expression of protease activated receptor 2 (PAR-2) in seasonal allergic conjunctivitis: a role for abnormal conjunctival epithelial permeability in disease pathogenesis? Br J Ophthalmol 2011; 95:1304-1308.
39. Wakamatsu TH, Tanaka M, Satake Y, et al. Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis. Mol Vis 2011; 17:932-938.
40. Pong JC, Chu CY, Chu KO, et al. Identification of hemopexin in tear film. Anal Biochem 2010; 404:82-85.
41. Pong JC, Chu CY, Li WY, et al. Association of hemopexin in tear film and conjunctival macrophages with vernal keratoconjunctivitis. Arch Ophthalmol 2011; 129:453-461.
42. Mantelli F, Micera A, Sacchetti M, Bonini S. Neurogenic inflammation of the ocular surface. Curr Opin Allergy Clin Immunol 2010; 10:498-504.
43. Sacchetti M, Micera A, Lambiase A, et al. Tear levels of neuropeptides increase after specific allergen challenge in allergic conjunctivitis. Mol Vis 2011; 17:47-52.